Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Longeveron. The associated price target remains the same with $4.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Michael Okunewitch has given his Buy rating due to a combination of factors including Longeveron’s progress in their clinical trials and the potential for significant catalysts. The company’s ELPIS II trial for treating hypoplastic left heart syndrome (HLHS) has completed enrollment, and the anticipated topline results in the third quarter of 2026 could be pivotal. A positive outcome from this trial could position Longeveron to file for approval, which would be a major milestone for the company.
Additionally, the favorable regulatory environment for cell-based therapies, as evidenced by the success of Mesoblast’s Ryoncil, provides an external tailwind that could benefit Longeveron. The company’s strategic adjustments, such as extending BLA filing expectations to optimize costs, and its efforts to secure additional funding, further support the Buy rating. These internal and external factors combined suggest a promising outlook for Longeveron’s stock.
In another report released yesterday, Roth MKM also reiterated a Buy rating on the stock with a $3.00 price target.